National Epilepsy Action Plan

Summary#

This bill creates a new federal program called the National Plan for Epilepsy. It directs the Secretary of Health and Human Services to build and run a coordinated national plan for preventing, diagnosing, treating, and curing epilepsy. The plan includes regular assessments, an advisory council, annual reports to Congress, and a requirement that federal agencies share epilepsy-related data with HHS.

• Main change: adds a new federal program and duties for the Secretary to coordinate epilepsy research, care, and public information across agencies.
• Creates an Advisory Council made up of federal agency representatives and appointed non-federal experts, patients, caregivers, clinicians, researchers, and nonprofit representatives.
• Requires assessments and reports: an initial assessment within 2 years, annual assessments, an Advisory Council report within 18 months and then every 2 years, and annual reports to Congress.
• Requires agencies to share epilepsy-related data with the Secretary to support reporting and planning.
• Sunset: the new section ends on December 31, 2035.
• What is unclear: the bill does not set specific funding amounts, staff levels, or enforcement rules for carrying out the plan.

What it means for you#

• People with epilepsy and caregivers

  • Could benefit from a more coordinated federal effort to improve diagnosis, access to specialists, treatments, and quality-of-life programs.
  • May be able to submit public comments that the plan must consider.
  • Could see goal-driven efforts to reduce stigma, financial burdens, and epilepsy-related deaths.

• Clinicians and researchers

  • Federal coordination could make it easier to find research partners and to align research priorities across agencies.
  • Advisory Council includes slots for clinicians and researchers, so experts can advise federal decision-makers.

• Nonprofit organizations focused on epilepsy

  • May be asked to participate in reports, advisory council activities, and public meetings.
  • Might see more federal attention to service gaps and public awareness.

• Federal agencies (NIH, CDC, FDA, CMS, HRSA, DOD, VA, etc.)

  • Must appoint representatives to the Advisory Council and share epilepsy-related data with HHS.
  • Will be asked to coordinate activities and may adapt programs to match the National Plan’s priorities.

• General public

  • Advisory Council meetings must be open to the public, so the process will be more visible.
  • Annual reports to Congress will summarize federal efforts and progress.

If you are not in the groups above, the bill mainly changes how the federal government organizes and reports on epilepsy efforts; it does not directly change benefit rules, insurance coverage, or specific clinical practices on its own.

Expenses#

No publicly available information.

• The bill does not specify new funding amounts or an approved budget.
• Creating and running the National Plan, the Advisory Council, and the required assessments and reports will likely require staff time and administrative support at HHS and at participating agencies. This could increase agency operating costs, but the bill does not state how those costs will be paid.
• Agencies will need to manage data-sharing tasks; that could require IT, privacy, or legal work not addressed in the text.
• The sunset date (December 31, 2035) suggests costs are planned for a limited period, but no cost estimates are provided.

Proponents' View#

The bill appears intended to do the following:

• Coordinate federal research and services so efforts across multiple agencies are less duplicated and more aligned.
• Set national priorities and regular assessments to track progress in preventing, diagnosing, treating, and curing epilepsy.
• Improve early diagnosis, care coordination, and access to specialist services for people with epilepsy.
• Encourage development of better treatments and approaches to reduce seizures, improve functioning, and lower epilepsy-related deaths.
• Increase public awareness and reduce stigma by requiring public meetings and outreach as part of the plan.

Opponents' View#

The bill’s design raises several plausible concerns or trade-offs:

• The bill does not set or authorize specific funding levels. One concern is that without dedicated funding, the plan may be under-resourced and have limited effect.
• It leaves many implementation details to the Secretary of HHS (for example, how activities are prioritized and how agencies coordinate), which could reduce transparency or slow action.
• Data-sharing requirements do not specify privacy protections or technical standards. This may create logistical or privacy challenges when agencies share health data.
• Regular reporting and quarterly advisory council meetings will require staff time at HHS and other agencies, creating administrative costs that are not estimated in the bill.
• The program ends in 2035 unless extended, which could disrupt long-term research or services that need continuity beyond that date.